Enveric Biosciences announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENVB: